These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tyro3, Axl, and Mertk receptors differentially participate in platelet activation and thrombus formation. Zhou J; Yang A; Wang Y; Chen F; Zhao Z; Davra V; Suzuki-Inoue K; Ozaki Y; Birge RB; Lu Q; Wu Y Cell Commun Signal; 2018 Dec; 16(1):98. PubMed ID: 30541554 [TBL] [Abstract][Full Text] [Related]
3. MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Knubel KH; Pernu BM; Sufit A; Nelson S; Pierce AM; Keating AK Oncotarget; 2014 Mar; 5(5):1338-51. PubMed ID: 24658326 [TBL] [Abstract][Full Text] [Related]
4. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity. Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426 [TBL] [Abstract][Full Text] [Related]
5. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma. Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482 [TBL] [Abstract][Full Text] [Related]
6. Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow. Jung Y; Decker AM; Wang J; Lee E; Kana LA; Yumoto K; Cackowski FC; Rhee J; Carmeliet P; Buttitta L; Morgan TM; Taichman RS Oncotarget; 2016 May; 7(18):25698-711. PubMed ID: 27028863 [TBL] [Abstract][Full Text] [Related]
7. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568 [TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinases Tyro3, Axl, and Mertk differentially contribute to antibody-induced arthritis. Gao L; He C; Yang A; Zhou H; Lu Q; Birge RB; Wu Y Cell Commun Signal; 2023 Aug; 21(1):195. PubMed ID: 37537628 [TBL] [Abstract][Full Text] [Related]
9. AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Axelrod HD; Valkenburg KC; Amend SR; Hicks JL; Parsana P; Torga G; DeMarzo AM; Pienta KJ Mol Cancer Res; 2019 Feb; 17(2):356-369. PubMed ID: 30291220 [TBL] [Abstract][Full Text] [Related]
10. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells. Al Kafri N; Hafizi S Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510 [TBL] [Abstract][Full Text] [Related]
11. GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. Taichman RS; Patel LR; Bedenis R; Wang J; Weidner S; Schumann T; Yumoto K; Berry JE; Shiozawa Y; Pienta KJ PLoS One; 2013; 8(4):e61873. PubMed ID: 23637920 [TBL] [Abstract][Full Text] [Related]
12. TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer. Dufour F; Silina L; Neyret-Kahn H; Moreno-Vega A; Krucker C; Karboul N; Dorland-Galliot M; Maillé P; Chapeaublanc E; Allory Y; Stransky N; Haegel H; Menguy T; Duong V; Radvanyi F; Bernard-Pierrot I Br J Cancer; 2019 Mar; 120(5):555-564. PubMed ID: 30765874 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity. Nguyen KQ; Tsou WI; Calarese DA; Kimani SG; Singh S; Hsieh S; Liu Y; Lu B; Wu Y; Garforth SJ; Almo SC; Kotenko SV; Birge RB J Biol Chem; 2014 Sep; 289(37):25737-49. PubMed ID: 25074939 [TBL] [Abstract][Full Text] [Related]
16. Saito T; Itoh M; Tohda S Anticancer Res; 2022 Apr; 42(4):1757-1761. PubMed ID: 35346994 [TBL] [Abstract][Full Text] [Related]
17. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Myers KV; Amend SR; Pienta KJ Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471 [TBL] [Abstract][Full Text] [Related]
18. The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer. Uribe DJ; Mandell EK; Watson A; Martinez JD; Leighton JA; Ghosh S; Rothlin CV PLoS One; 2017; 12(7):e0179979. PubMed ID: 28727830 [TBL] [Abstract][Full Text] [Related]
19. Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders. Gadiyar V; Patel G; Chen J; Vigil D; Ji N; Campbell V; Sharma K; Shi Y; Weiss MM; Birge RB; Davra V Front Immunol; 2023; 14():1135373. PubMed ID: 37545504 [TBL] [Abstract][Full Text] [Related]
20. The TAM-family receptor Mer mediates production of HGF through the RhoA-dependent pathway in response to apoptotic cells. Park HJ; Baen JY; Lee YJ; Choi YH; Kang JL Mol Biol Cell; 2012 Aug; 23(16):3254-65. PubMed ID: 22740630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]